The elimination half-life range of quazepam is between 27 and 41 hours. Mechanism of action
Quazepam modulates specific GABAA receptors via the benzodiazepine site on the GABAA receptor. This modulation enhances the actions of GABA, causing an increase in opening frequency of the chloride ion channel which results in an increased influx of chloride ions into the GABAA receptors. Quazepam, unique amongst benzodiazepine drugs selectively targets type1 benzodiazepine receptors which results reduced sleep latency in promotion of sleep. Quazepam also has some anticonvulsant properties. EEG and sleep
Quazepam has potent sleep inducing and sleep maintaining properties. Studies in both animals and humans have demonstrated that EEG changes induced by quazepam resemble normal sleep patterns whereas other benzodiazepines disrupt normal sleep. Quazepam promotes slow wave sleep. This positive effect of quazepam on sleep architecture may be due to its high selectivity for type1 benzodiazepine receptors as demonstrated in animal and human studies. This makes quazepam unique in the benzodiazepine family of drugs. Drug misuse
Quazepam is a drug with the potential for misuse. Two types of drug misuse can occur, either recreational misuse where the drug is taken to achieve a high, or when the drug is continued long term against medical advice. References
External links
"Quazepam". Drug Information Portal. U.S. National Library of Medicine.
Magnesium salicylate is a common analgesic and nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate musculoskeletal pain such as in tendons and muscles. It is also used to treat joint pain like arthritis, general back pain, and headaches.It is found in a variety of over-the-counter (OTC) medications, most notably the brand Doans Pills, as an anti-inflammatory, primarily for back-pain relief. Magnesium salicylate can be an effective OTC alternative to prescription NSAIDs, with both anti-inflammatory and pain-relieving effects. Controversy
While magnesium salicylate is sold as an alternative for pain relief, it is still a nonsteroidal anti-inflammatory drug and, like others in this class, can cause stomach ulcers,  without any proven superiority to other over-the-counter pain relievers. Novartis, the company (formerly known as Ciba or Ciba-Geigy Corp.) that produces Doans Pills, has claimed that the product is superior in providing back pain relief. In June 1996, the US Federal Trade Commission (FTC) charged the company with violating federal law with its unsubstantiated claim. In March 1998, the court ruled in favor of the FTC, but there was no stipulation about how the company should or would have to amend its advertising/packaging. Thus, Doans was able to continue marketing as a "superior treatment for back pain".